Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock Holdings Increased by SG Americas Securities LLC

SG Americas Securities LLC grew its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 119.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 19,961 shares of the company’s stock after buying an additional 10,845 shares during the quarter. SG Americas Securities LLC’s holdings in Mineralys Therapeutics were worth $246,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. The Manufacturers Life Insurance Company acquired a new stake in shares of Mineralys Therapeutics during the 2nd quarter valued at approximately $145,000. China Universal Asset Management Co. Ltd. increased its stake in Mineralys Therapeutics by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,564 shares of the company’s stock valued at $116,000 after purchasing an additional 3,732 shares during the last quarter. Jennison Associates LLC raised its holdings in shares of Mineralys Therapeutics by 1.9% during the third quarter. Jennison Associates LLC now owns 696,280 shares of the company’s stock worth $8,432,000 after purchasing an additional 13,023 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Mineralys Therapeutics by 4.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 213,599 shares of the company’s stock worth $2,587,000 after buying an additional 9,664 shares during the last quarter. Finally, FMR LLC boosted its holdings in shares of Mineralys Therapeutics by 12.0% in the 3rd quarter. FMR LLC now owns 303,758 shares of the company’s stock valued at $3,679,000 after buying an additional 32,663 shares during the period. Institutional investors and hedge funds own 84.46% of the company’s stock.

Insider Buying and Selling at Mineralys Therapeutics

In related news, CEO Jon Congleton sold 18,333 shares of Mineralys Therapeutics stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $9.06, for a total transaction of $166,096.98. Following the sale, the chief executive officer now directly owns 877,608 shares in the company, valued at $7,951,128.48. The trade was a 2.05 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Adam Scott Levy sold 10,757 shares of the company’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $9.10, for a total transaction of $97,888.70. Following the completion of the sale, the chief financial officer now directly owns 226,097 shares of the company’s stock, valued at $2,057,482.70. The trade was a 4.54 % decrease in their position. The disclosure for this sale can be found here. 33.24% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a research note on Tuesday, November 12th.

Mineralys Therapeutics Price Performance

NASDAQ:MLYS opened at $10.05 on Friday. The firm has a market capitalization of $500.19 million, a P/E ratio of -3.07 and a beta of 1.44. The business has a 50 day simple moving average of $11.51 and a 200 day simple moving average of $12.15. Mineralys Therapeutics, Inc. has a 12-month low of $8.58 and a 12-month high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its quarterly earnings results on Monday, November 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.30). During the same quarter in the prior year, the business earned ($0.57) EPS. Research analysts anticipate that Mineralys Therapeutics, Inc. will post -3.63 EPS for the current fiscal year.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.